Kowa, Eli Lilly report results of pre-specified safety analysis of INTREPID trial

Kowa Pharmaceuticals America and Eli Lilly and Company have reported results of the pre-specified safety analysis from the INTREPID trial, a phase IV study designed to evaluate Livalo (pitavastatin) 4mg against pravastatin 40mg in HIV-infected patien…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news